Immunome Inc (IMNM) Stock Price, Quote & News

Company Profile

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 425 939 7410

Website: immunome.com

Address:

18702 North Creek Parkway, Suite 100, Bothell, United States

RadioIsotope25 Mar. 15 at 3:23 PM

Radiopharmaceutical buyouts and Market Caps $RADX $IMNM $PYXS $CELC

1 · Reply

RadioIsotope25 Mar. 13 at 4:43 PM

Diamond in the Rough $RADX $PYXS $IMNM $SMMT $AKTS

0 · Reply

EingeLTrade Mar. 10 at 1:56 PM

Added more $IMNM

0 · Reply

RadioIsotope25 Mar. 6 at 12:18 AM

$30 target @ Jones Trading for Radiopharm Theranostics. $IMNM $PYXS $SLS $IOVA $RADX

3 · Reply

OfficialStocktwitsUser Mar. 4 at 2:57 PM

$IMNM RSI: 41.24, MACD: -0.3808 Vol: 1.37, MA20: 22.85, MA50: 22.76 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

d_risk Mar. 3 at 9:27 PM

$IMNM - Immunome Inc - 10K - Updated Risk Factors IMNM’s 2026 10-K sharpens early-stage and financing risk (no NDA/BLA, no near-term revenue, capital-intensive R&D) while adding program-specific IM‑3050 uncertainty, heavier dependence on ADC platform and in-licensed IP, broader global/regulatory and orphan/companion diagnostic hurdles, deeper patent and trademark vulnerability, expanded misconduct and anti-takeover concerns, and new litigation and Nasdaq compliance risks, even as some prior funding, foreign market, and analyst-coverage risks are pared back or reframed. #PharmaceuticalCommercialization #CompetitiveRisk #SupplyChainRisk #RegulatoryUncertainty #Biotechnology #EarlyStageRisk #CapitalIntensiveR&D #RegulatoryChallenges #IntellectualPropertyRisk 🟢 Added 🟠 Removed https://d-risk.ai/IMNM/10-K/2026-03-03

0 · Reply

d_risk Mar. 3 at 9:21 PM

0 · Reply

RadioIsotope25 Feb. 28 at 4:39 PM

$RADX Terbium and Lutetium $AKTS $CATX $IMNM https://youtu.be/AOalQM8zfDM

0 · Reply

BillionerOfKing Feb. 25 at 12:41 AM

$IMNM Current Stock Price: $22.11 Contracts to trade: $22.0 IMNM Mar 20 2026 Call Entry: $0.65 Exit: $0.91 ROI: 39% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

RadioIsotope25 Feb. 24 at 5:32 PM

AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01) $RADX $CATX $LNTH $IMNM https://www.prnewswire.co.uk/news-releases/atomvie-global-radiopharma-supplies-first-patient-dose-in-radiopharm-theranostics-phase-12a-clinical-study-of-177lu-betabart-rv-01-302695311.html

0 · Reply

Immunome: Upcoming NDA, Valuation, And Investment Case

Mar 5, 2026, 4:00 PM EST - 10 days ago

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 3, 2026, 4:02 PM EST - 12 days ago

Immunome Reports Full Year 2025 Financial Results and Provides Business Update

Feb 23, 2026, 8:00 AM EST - 21 days ago

Immunome to Present at Upcoming Investor Conferences

Feb 4, 2026, 8:00 AM EST - 5 weeks ago

Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 6, 2026, 8:00 AM EST - 2 months ago

Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 2:44 PM EST - 3 months ago

Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat

Dec 16, 2025, 8:16 PM EST - 3 months ago

Immunome Announces Pricing of Public Offering of Common Stock

Dec 15, 2025, 4:01 PM EST - 3 months ago

Immunome Announces Proposed Public Offering of Common Stock

Dec 15, 2025, 7:16 AM EST - 3 months ago

Immunome's experimental drug meets main goal in late-stage study

Dec 15, 2025, 7:00 AM EST - 3 months ago

Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Dec 14, 2025, 4:00 PM EST - 3 months ago

Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Nov 6, 2025, 4:05 PM EST - 4 months ago

Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 31, 2025, 11:51 AM EDT - 4 months ago

Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference

Oct 23, 2025, 12:00 PM EDT - 5 months ago

Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance

Sep 18, 2025, 8:00 AM EDT - 6 months ago

Infinimmune Announces Research Collaboration with Immunome

Sep 3, 2025, 8:00 AM EDT - 6 months ago

Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 11, 2025, 10:31 PM EDT - 7 months ago

Immunome: SpringWorks Buyout Informs The Potential Upside Here

Aug 6, 2025, 4:05 PM EDT - 7 months ago

Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:05 PM EDT - 10 months ago

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 17, 2025, 6:06 AM EDT - 11 months ago

Immunome: Transformed Pipeline Offers Multiple Catalysts

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 19, 2025, 4:05 PM EDT - 1 year ago

Immunome Reports Full Year 2024 Financial Results and Provides Business Update

Mar 10, 2025, 7:41 AM EDT - 1 year ago

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC

Feb 25, 2025, 8:00 AM EST - 1 year ago

Immunome to Present at Upcoming March Conferences

Jan 31, 2025, 4:01 PM EST - 1 year ago

Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 30, 2025, 10:27 AM EST - 1 year ago

Immunome Can Take The Fight To Competitors With Varegacestat

Jan 29, 2025, 11:11 PM EST - 1 year ago

Immunome Announces Pricing of Upsized Public Offering of Common Stock

Jan 13, 2025, 8:00 AM EST - 1 year ago

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 1 year ago

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 13, 2024, 4:05 PM EST - 1 year ago

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 5, 2024, 8:00 AM EST - 1 year ago

Immunome to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Oct 18, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

Oct 8, 2024, 8:05 AM EDT - 1 year ago

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 25, 2024, 8:00 AM EDT - 1 year ago

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

Jun 27, 2024, 2:14 PM EDT - 1 year ago

Immunome: AL102 And Other Established Protein Targets Could Drive Value

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Immunome Appoints Phil Tsai as Chief Technical Officer

May 20, 2024, 8:00 AM EDT - 1 year ago

Immunome Announces Completion of Purchase of Assets from Atreca

May 17, 2024, 8:00 AM EDT - 1 year ago

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

May 14, 2024, 8:00 AM EDT - 1 year ago

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024, 8:00 AM EDT - 2 years ago

Immunome to Present at 2024 Bank of America Healthcare Conference

May 2, 2024, 8:00 AM EDT - 2 years ago

Immunome Appoints Kinney Horn as Chief Business Officer

Apr 25, 2024, 8:26 AM EDT - 2 years ago

Immunome Appoints Sandra M. Swain to Board of Directors

Apr 5, 2024, 8:00 AM EDT - 2 years ago

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

Apr 2, 2024, 2:07 PM EDT - 2 years ago

Immunome: An Oncology Powerhouse In The Making

Mar 28, 2024, 4:02 PM EDT - 2 years ago

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

RadioIsotope25 Mar. 15 at 3:23 PM

Radiopharmaceutical buyouts and Market Caps $RADX $IMNM $PYXS $CELC

1 · Reply

RadioIsotope25 Mar. 13 at 4:43 PM

Diamond in the Rough $RADX $PYXS $IMNM $SMMT $AKTS

0 · Reply

EingeLTrade Mar. 10 at 1:56 PM

Added more $IMNM

0 · Reply

RadioIsotope25 Mar. 6 at 12:18 AM

$30 target @ Jones Trading for Radiopharm Theranostics. $IMNM $PYXS $SLS $IOVA $RADX

3 · Reply

OfficialStocktwitsUser Mar. 4 at 2:57 PM

0 · Reply

d_risk Mar. 3 at 9:27 PM

0 · Reply

d_risk Mar. 3 at 9:21 PM

0 · Reply

RadioIsotope25 Feb. 28 at 4:39 PM

$RADX Terbium and Lutetium $AKTS $CATX $IMNM https://youtu.be/AOalQM8zfDM

0 · Reply

BillionerOfKing Feb. 25 at 12:41 AM

0 · Reply

RadioIsotope25 Feb. 24 at 5:32 PM

0 · Reply

MachineLearningAlpha Feb. 20 at 12:57 PM

$IMNM Immunome develops antibody-based cancer therapies. Clinical data drives valuation. Development timelines are long.

0 · Reply

RadioIsotope25 Feb. 17 at 6:08 PM

$RADX $AKTS $CATX $IMNM

0 · Reply

flam70 Feb. 12 at 12:54 PM

$IMNM wainwright initiates with a buy and a $40 price target

0 · Reply

Wagner76 Feb. 11 at 4:40 PM

$IMNM What is going on today? Every time it appears this stock is going on a run, it goes in a fast retreat. Any news, or just another sell off?

1 · Reply

JFDI Feb. 10 at 4:50 PM

$IMNM set 2 go?

0 · Reply

RadioIsotope25 Feb. 6 at 2:34 PM

$RADX Last two $LNTH acquisitions have been averaged $350 million. They own 15% of RADX and they have a plug and play brain mets Phase2b radio imaging asset preparing for a phase3 (would be #3 biggest radio imaging agent globally behind Telix and Lantheus two leaders I. Prostate) + they have a pipeline full of designer radiopharmaceuticals and more on the way from MD Anderson. At $60 million market cap you do the math. $IMNM $PYXS $IBRX

0 · Reply

Smellmahass Feb. 4 at 3:51 PM

$IMNM I knew it. Great long term.

1 · Reply

TalkMarkets Feb. 4 at 10:41 AM

This Price Zone Has Saved The S&P 500 4 Times In A Row (Here's Why) $SPX $CIEN $IMNM $LECO https://talkmarkets.com/content/stocks--equities/this-price-zone-has-saved-the-sp-500-4-times-in-a-row-heres-why?post=554744&userid=166882

0 · Reply

ErosROI Feb. 4 at 9:32 AM

$IMNM immunology biotech, clinical-stage

1 · Reply

HunterT Feb. 3 at 11:22 PM

$IMNM the silent march to the 30s begins

0 · Reply

ripster47 Jan. 23 at 12:18 PM

$IMNM 🚨 🚀 Big Winner from our Swing Idea from Last month See Before/After One of Repeatable Swing Setups taught by @ripster47 Biotech Swing See how price bounced from EMA Clouds & Support Level. Stop moved up Follow us for more Setups & Swing Charts at @TenetCharts

0 · Reply

Market Cap	2.30B
Revenue (ttm)	6.94M
Net Income (ttm)	-212.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,060.37%
Debt to Equity Ratio	0.00

Volume	983,500
Avg Vol	1,532,976
Day's Range	N/A - N/A
Shares Out	113.13M
Stochastic %K	18%
Beta	2.12
Analysts	Strong Sell
Price Target	$35.54